Data Insights

MRG-002 by Shanghai Miracogen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Gastroesophageal (GE) Junction Carcinomas

Data Insights

MRG-002 by Shanghai Miracogen for Metastatic Breast Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Metastatic Breast Cancer

Data Insights

MRG-002 by Shanghai Miracogen for Gastric Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Gastric Cancer

Data Insights

MRG-002 by Shanghai Miracogen for Bladder Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Bladder Cancer

Data Insights

MRG-002 by Shanghai Miracogen for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

MRG-002 by Shanghai Miracogen for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)